Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.
WAT - Waters Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$453.50
DETAILS
HIGH:
$515.00
LOW:
$387.00
MEDIAN:
$455.00
CONSENSUS:
$453.50
UPSIDE:
4.55%
Stock News
Waters (NYSE:WAT) Reaches New 52-Week High – Time to Buy?
Shares of Waters Corporation (NYSE: WAT - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $454.54 and last traded at $444.9030, with a volume of 52745 shares changing hands. The stock had previously closed at $440.12. Wall Street Analysts Forecast Growth WAT has been the subject
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
MILFORD, Mass., Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m.
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
Waters NYSE: WAT President and Chief Executive Officer Udit Batra said the company's second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses.
Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript
Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript
Still Waters Bring Mixed Pre-Market Levels
A grand total of zero monthly or quarterly economic reports have come out so far this week.
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening tool available in the U.S. today, the Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay.1 The new diagnostic-led solution supports health plans as they expand access to cervical cancer screening and make it easier for eligible members to complete recom.
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization for greater confidence in results.
Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
MILFORD, Mass., Sept. 11, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.
Waters Corporation (WAT) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Waters Corporation (WAT) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters Corporation $WAT Shares Purchased by Benjamin Edwards Inc.
Benjamin Edwards Inc. lifted its holdings in shares of Waters Corporation (NYSE: WAT) by 72.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,189 shares of the medical instruments supplier's stock after purchasing an additional 1,760 shares during the
This Waters Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WEST CHESTER, Ohio--(BUSINESS WIRE)--LetsGetChecked now offers the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S.
Waters Corporation to Present at the Wells Fargo Healthcare Conference
MILFORD, Mass., Aug. 26, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.
Bank of Nova Scotia Sells 3,735 Shares of Waters Corporation $WAT
Bank of Nova Scotia cut its stake in shares of Waters Corporation (NYSE: WAT) by 27.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,923 shares of the medical instruments supplier's stock after selling 3,735 shares during the period.
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Assetmark Inc. Has $1.57 Million Stake in Waters Corporation $WAT
Assetmark Inc. lowered its holdings in Waters Corporation (NYSE: WAT) by 56.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,196 shares of the medical instruments supplier's stock after selling 5,449 shares during the period. Assetmark Inc.'s holdings in Waters were
Dudley & Shanley Inc. Has $8.85 Million Stake in Waters Corporation $WAT
Dudley and Shanley Inc. raised its holdings in Waters Corporation (NYSE: WAT) by 101.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,590 shares of the medical instruments supplier's stock after purchasing an additional 11,870 shares during the period. Waters makes
Price Targets
Waters price target raised to $500 from $460 at Barclays
$500.00
(was $436.45)
Barclays
Waters price target raised to $490 from $440 at Guggenheim
$490.00
(was $436.32)
Subbu Nambi
·
Guggenheim
Waters price target raised to $515 from $465 at Goldman Sachs
$515.00
(was $421.63)
Evie Koslosky
·
Goldman Sachs
Waters assumed with a Buy at UBS
$490.00
(was $402.91)
Doug Schenkel
·
UBS
Waters upgraded to Overweight from Neutral at Piper Sandler
$480.00
(was $414.17)
Piper Sandler
Waters price target raised to $430 from $390 at Morgan Stanley
$430.00
(was $400.03)
Morgan Stanley
Waters price target raised to $400 from $380 at Deutsche Bank
$400.00
(was $398.49)
Deutsche Bank
Waters price target raised to $420 from $410 at Evercore ISI
$420.00
(was $394.18)
Vijay Kumar
·
Evercore ISI
Waters price target raised to $475 from $435 at RBC Capital
$475.00
(was $394.58)
RBC Capital
Waters price target raised to $420 from $380 at Stifel
$420.00
(was $396.08)
Daniel Arias
·
Stifel Nicolaus
Waters price target raised to $460 from $425 at Barclays
$460.00
(was $396.08)
Luke Sergott
·
Barclays
Waters price target raised to $425 from $380 at Goldman Sachs
$425.00
(was $373.22)
Evie Koslosky
·
Goldman Sachs
Waters price target raised to $390 from $350 at Morgan Stanley
$390.00
(was $368.13)
Kallum Titchmarsh
·
Morgan Stanley
Waters initiated with an Outperform at RBC Capital
$435.00
(was $368.13)
RBC Capital
Waters price target raised to $410 from $380 at Evercore ISI
$410.00
(was $375.38)
Evercore ISI
Waters initiated with a Neutral at Piper Sandler
$400.00
(was $363.18)
Piper Sandler
Waters price target raised to $435 from $415 at HSBC
$435.00
(was $371.93)
HSBC
Waters price target raised to $350 from $330 at Deutsche Bank
$350.00
(was $351.33)
Deutsche Bank
Waters price target raised to $425 from $400 at Barclays
$425.00
(was $349.53)
Barclays
Waters price target raised to $375 from $330 at UBS
$375.00
(was $352.64)
UBS